research misconduct and previously
violative inspections. The majority of
SIB-related warning letters were the
result of research misconduct complaints. Other warning letters issued
were related to repeat offenders and
other surveillance inspections.
BIMO’s Program Enforcement
Branch issued nine warning letters,
due primarily to CDRH’s early intervention and marketing application
activities. Early intervention activities
research entities with previously violative inspections tend to be repeat
offenders. On the other hand, CDRH
issued 77% of the warning letters to
sites that FDA inspected for the first
time (see Figure 5). In most cases,
systemic issues such as lack of GCP
training, lack of management or supervisory oversight, and ineffective
corrective and preventive actions were
the primary causes of warning letter
issuance.
Warning Letter Response
When a regulated entity receives
a warning letter, the recipient must
provide a response within 15 days of
receipt. In some cases, CDRH BIMO
grants extensions in order for the regulated entity to provide its clear and
Research entities with
previously violative
inspections tend to be
repeat offenders.
are risk based and focus on active IDE
studies of novel technologies, vulnerable populations, or significant public
health issues. It is interesting to note
that CDRH BIMO inspections conducted pursuant to marketing applications (i.e., PMA, 510(k), etc.) resulted in
the issuance of just two warning letters
in FY 2007, none of which generated
data reliability concerns. One explanation is that BIMO’s early intervention
program sensitizes device firms to the
importance of well-managed clinical
trials during the active research phase,
leading to marketing applications with
higher-quality studies.
CDRH BIMO issued 23% of the
warning letters to sites that had a previous BIMO inspection. Of the seven
sites that had a previous BIMO inspection, nearly three-quarters of those
sites had a previously violative inspection (i.e., had received at least a warning letter). Based on this information,
31%
69%
Program Enforcment Branch
Special Investigations Branch
Figure 4. CDRH BIMO warning letters by
branch.
Introducing Rapid Custom Manufacturing
Imagine a tool that lets you make
completely custom products for any patient,
from a wide range of FDA-approved material.
A single machine able to scale with your
growth, from R&D to full production. One
that is flexible and easy enough to operate
without expensive technicians or software.
And affordable enough to replicate as
production increases, at a fraction of the
cost of large CNC mills.
This is the thinking behind Roland Rapid
Custom Manufacturing (RCM) solutions.
Visit our website or call for more information
and the name of your nearest Roland
Authorized Dealer.
www.RolandDGA.com/RCM
888-273-8895
Certified ISO 9001:2000 ©2008 Roland DGA Corp.